The Vanguard Group, Inc. recently announced the acquisition of new stake in ZIOPHARM Oncology Inc. (NASDAQ:ZIOP). The institutional investor has increased its shareholding in the Healthcare company by 2.37% to 14.94 million shares with purchase of 0.35 million shares. This fresh investment now brings its stake to 6.97% valued currently at $44.37 million. In addition, BlackRock Fund Advisors raised its holdings by 1.92 million to 13.64 million shares. And Discovery Capital Management LLC has lifted its position by 1.05% or 100000.0 shares – to 9.64 million shares.

With over 1.12 million ZIOPHARM Oncology Inc. (ZIOP) shares trading Tuesday and a closing price of $2.73 on the day, the dollar volume was approximately $3.06 million. The shares have shown a negative weekly performance of -4.88% and its price on 08/25/20 lost nearly -0.36%. Currently, there are 212.79M common shares owned by the public and among those 200.16M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for ZIOP have a consensus price objective of $5.93. The analysts have set the share’s price value over the next 12 months at a high of $7.50 and a low of $3.00 should the stock experience a downside. Incidentally, analysts’ outlook for the ZIOPHARM Oncology Inc. stock is 2.20 for the next 12 months. But an upside of 63.6% will see the stock hit the forecast high price target while mean target price for the stock is $6.00.

Insiders at the company have transacted a total of 22 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 13 of these insider trades were purchases, accounting for 684,739 shares. Insider sales of the common stock occurred on 9 occasions, with total insider shares sold totaling 296,152 shares.

The top 3 mutual fund holders in ZIOPHARM Oncology Inc. are Miller Opportunity Trust, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. Miller Opportunity Trust owns 9.6 million shares of the company’s stock, all valued at over $28.51 million. The company sold -0.4 million shares recently to bring their total holdings to about 4.48% of the shares outstanding. Vanguard Total Stock Market Index sold 3123.0 shares to see its total holdings shrink to 6.15 million shares valued at over $18.26 million and representing 2.87% of the shares outstanding. iShares Russell 2000 ETF sold -0.2 million shares to bring its total holdings to over 4.37 million shares at a value of $12.97 million. iShares Russell 2000 ETF now owns shares totaling to 2.04% of the shares outstanding.

Shares of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) opened at $2.74, unchanged from a prior closing price of $2.74. However, the script later closed the day at $2.73, down -0.36%. The company’s stock has a 5-day price change of -4.88% and -21.78% over the past three months. ZIOP shares are trading -42.16% year to date (YTD), with the 12-month market performance down to -46.89% lower. It has a 12-month low price of $1.79 and touched a high of $5.61 over the same period. Currently, 1.12 million shares have been traded, compared to an average intraday trading volume of 2.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.89%, -15.11%, and -22.13% respectively.

Institutional ownership of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) shares accounts for 54.90% of the company’s 212.79M shares outstanding. Mutual fund holders own 21.29%, while other institutional holders and individual stakeholders account for 31.17% and 17.97% respectively.

It has a market capitalization of $596.89M and a beta (3y monthly) value of 2.32. The earnings-per-share (ttm) stands at -$0.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.80% over the week and 6.42% over the month.

Analysts forecast that ZIOPHARM Oncology Inc. (ZIOP) will achieve an EPS of -$0.09 for the current quarter, -$0.09 for the next quarter and -$0.41 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.1 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.43 a year ago. Earnings per share for the fiscal year are expected to decrease by -173.40%, and -10.80% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate ZIOPHARM Oncology Inc. (ZIOP) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 1 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the ZIOP, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on June 19, 2020, with the firm’s price target at $7. Cantor Fitzgerald coverage for the ZIOPHARM Oncology Inc. (ZIOP) stock in a research note released on March 04, 2020 offered a Overweight rating with a price target of $6. Raymond James was of a view on August 23, 2019 that the stock is Outperform, while Lake Street gave the stock Buy rating on April 04, 2019, issuing a price target of $7. Laidlaw on their part issued Buy rating on April 01, 2019.